About This Webinar:
All clinically prescribed antipsychotics act by essentially blocking dopamine D2 G protein Coupled Receptors (GPCR) in the brain. We now understand that depending on the biochemical make-up of cells or neurons, a GPCR can engage distinct signaling pathways and affect distinct cellular responses. Validation of this new concept in genetically engineered mice has revealed that a novel "putative antipsychotic agent” can block D2 receptors in the motor area of the brain (striatum) but activate D2 receptors in the cognitive/executive function area (frontal cortex). A new antipsychotic with these properties might be more effective at alleviating both positive and negative symptoms of schizophrenia.
Click anywhere in the image below to play webinar recording.
Looking for the slides from this presentation? Download them here.
Marc G. Caron, Ph.D.
Foundation Scientific Council Member
2013 Recipient of the Lieber Prize for Outstanding Achievement in Schizophrenia Research
NARSAD Grantee, 2005
James B. Duke Professor of Cell Biology
Duke University Medical Center
Dr. Caron studies the mechanisms of action and regulation of hormones and neurotransmitters and how they might underlie brain and behavior disorders such as schizophrenia, Parkinson's disease, attention-deficit hyperactivity disorder, mood disorders and addiction. He and colleagues have identified a novel mode of signaling for the brain’s dopamine D2 receptors, representing a potential lead for the development of more effective medications with fewer side effects. They have also genetically engineered a “humanized” mouse model with a congenital deficit in serotonin that recapitulates many of the symptoms associated with animal models of depression. This model is being used to elucidate the neuronal circuits involved and to develop more selective and efficacious treatment strategies for mood disorders.
After postdoctoral training at Duke University, Dr. Caron joined the Laval University before joining the faculty at Duke.
Jeffrey Borenstein, M.D.
President & CEO, Brain & Behavior Research Foundation
Jeffrey Borenstein, M.D., joined the Brain & Behavior Research Foundation in 2012 as Chief Medical Officer and was appointed as President & Chief Executive Officer at the start of 2013. Dr. Borenstein has more than two decades of experience in health and non-profit leadership. He is former CEO/Medical Director of Holliswood Hospital, where he served from 1996 to 2012. He is a board-certified psychiatrist and the Host of the award-winning series, “Healthy Minds,” which is broadcast on public television stations across the United States. He is Editor-in-Chief of Psychiatric News, the newspaper of the American Psychiatric Association.
An active contributor to the psychiatric field for more than three decades, Dr. Borenstein currently chairs the Council on Communications of the American Psychiatric Association, the Mental Health Services Council of NY State, and the Section on Psychiatry, NY Academy of Medicine, where he is a Fellow. Among the many honors to his credit are the National Alliance on Mental Illness of NY State Connie Lieber Award, the American Psychiatric Association Special Presidential Commendation and the Federation of Organizations Community Mental Health Man of the Year Award.
Dr. Borenstein is Associate Clinical Professor of Psychiatry, Columbia University College of Physicians & Surgeons. He is a graduate of Harvard College and New York University School of Medicine.